文献速递淋巴瘤

基因组数据在预后模型中的转化损失:慢性淋巴细胞白血病中17p缺失与TP53突变的案例

Genomic data in prognostic models-what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia.
PubMed 文献 · Br J Haematol · 2019-03-05

该综述讨论基因组数据在血液肿瘤预后模型中的应用问题,以慢性淋巴细胞白血病(CLL)中17p缺失和TP53突变为范例,聚焦检测技术、临床显著性阈值及临床情境,指出将基因组数据简化为二元解读可能导致预后误判,强调将基因组学纳入预后模型时需审慎批判。

要点

  • 基因组数据常被二元化解读为缺失或突变的有无,这种过度简化可能导致预后误判。
  • TP53突变与包括CLL在内的多种血液恶性肿瘤的不良预后强相关。
  • 综述聚焦CLL中17p缺失或TP53突变用于预后分层的检测技术、临床显著性阈值及临床情境。

核心结论

  • CLL案例说明对基因检测的简单二元解读会引发问题,并强调将基因组学纳入预后模型时需持批判性视角。

研究设计与样本

  • 综述,聚焦CLL中利用17p缺失或TP53突变进行预后分层的研究,关注检测技术、临床显著性阈值及识别这些改变的临床情境。

主要发现

  • 基因组技术从细胞遗传学到二代测序产生数据,常被互换解读并二元化为特定染色体缺失或突变的有无。
  • TP53突变与包括CLL在内的多种血液恶性肿瘤的不良预后强相关。
  • 对基因检测的简单二元解读可能导致预后误判。

关键数值与推荐

  • TP53位于染色体17p,其序列和拷贝数改变被用作预后标志物。

临床怎么用

  • 将基因组学纳入预后模型时需持批判性视角。

局限性

  • 基因组数据常被二元化解读为缺失或突变的有无,这种过度简化可能带来预后误判的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Genomic technologies are revolutionizing the practice of haematology-oncology, leading to improved disease detection, more accurate prognostication and targeted treatment decisions. These advances, however, have also introduced new clinical challenges, which include problems of prognostic underdetermination and its attendant risks of over- and undertreatment. Genomic data is generated from different technologies, from cytogenetics to next-generation sequencing, which are often interpreted interchangeably and in a binary fashion-as the presence or absence of a given chromosomal deletion or mutation-an oversimplification which may lead to mistaken prognosis. We discuss the clinical use of one such prognostic marker, represented by sequence and copy number alterations in TP53, located on chromosome 17p. Mutations in TP53 are strongly linked to poor prognosis in a variety of haematological malignancies, including chronic lymphocytic leukaemia (CLL). We review studies in CLL which utilize the 17p deletion or TP53 mutations for prognostic stratification with specific focus on the technologies used for detection, the thresholds established for clinical significance, and the clinical contexts in which these alterations are identified. The case of CLL illustrates issues arising from simplistic, binary interpretation of genetic testing and highlights the need to apply a critical lens when incorporating genomics into prognostic models.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Chin-Yee B, Sadikovic B, Chin-Yee IH, et al. Genomic data in prognostic models-what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia. Br J Haematol. 2019. PMID: 30836431. doi:10.1111/bjh.15827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。